Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Verastem Oncology’s VS-7375.

Stevanato Group has secured €200 million in financing intended to support its ongoing capital expenditure projects in ...

Ipsen, a global specialty care biopharmaceutical company, has made the following changes to its Executive Committee: ...

AstraZeneca has announced a $50 billion investment in the United States by 2030, creating tens of thousands of new, highly ...

Jeff Sheehan, Managing Partner at Trinity Capital, Spark’s developer, commented, “Coriolis Pharma’s decision to establish ...

Abzena, an end-to-end integrated CDMO and CRO, has appointed Geoffrey M. Glass as Chief Executive Officer (CEO), effective ...

Solvias' Center of Excellence for biologics and novel modalities in Research Triangle Park, North Carolina, is now cGMP ready ...

Crown Bioscience’s San Diego laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification.

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

Operational strategies to optimize efficiency and cost effectiveness, and secure an unbroken chain of custody from ...

Sygnature Discovery has completed a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure.